Unichem Laboratories Limited — Board Meeting, 22-05-2025: Outcome of Board Meeting

Unichem Laboratories has announced a board meeting on approving the financial results for the quarter and half-year. Consolidated revenue reached ₹2,110.97 Cr for the year, with PAT bouncing back to ₹137.52 Cr from a prior loss, despite a ₹57.61 Cr exceptional charge related to a European fine. The company bolstered its US presence by acquiring nine ANDAs and the generics marketing business from Bayshore Pharmaceuticals. It’s also closing its UK manufacturing unit, centralizing production in India to cut costs. Key auditors were re-appointed to maintain governance standards.